Constellation Pharmaceuticals, Inc. (Constellation)

Oncology Corporate Profile

HQ Location

215 First Street, Suite 200
Cambridge, MA 2142

Company Description

Constellation Pharmaceuticals leverages insights from the rapidly expanding field of epigenetics to discover and develop small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The company's innovative product discovery engine targets both enzymes that modify the dynamic structure of chromatin (writers and erasers) and other proteins that interact with chromatin (readers) to control gene expression. Restoration of normal gene expression through chromatin modulation by highly selective and specific inhibitors promises to be a powerful approach to the development of important new medicines against a broad range of diseases.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CPI-0610BET protein bromodomain inhibitorMultiple MyelomaI
CPI-0610BET protein bromodomain inhibitorMyelodysplastic Syndrome (MDS)I
CPI-0610BET protein bromodomain inhibitorNon-Hodgkin's Lymphoma (NHL)I
CPI-1205EZH2 inhibitorNon-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »


Recent News Headlines

There are no news items to display